title: Interleukin-7 retroviruses transform pre-B cells by an autocrine mechanism not evident in Abelson murine.
abstract: In this study, we have constructed retroviral vectors expressing the interleukin-7 (IL-7) cDNA and have used infection with these retroviruses to express this cytokine endogenously in an IL-7-dependent pre-B-cell line. Infection with IL-7 retroviruses, but not with a control retrovirus, resulted in the conversion of the cells to IL-7 independence. The frequency at which this occurred, together with data on vector expression levels, indicated that secondary events were required for factor independence in this system. Southern analysis showed that the IL-7-dependent clones harbored unrearranged copies of the vector proviruses. The factor-independent cells produced variable quantities of IL-7 as measured by an IL-7-specific bioassay, and their proliferation could be substantially inhibited by a neutralizing antibody directed against IL-7, indicating that a classical autocrine-mechanism was responsible for their transformation. These IL-7-independent cells were tumorigenic, in contrast to the parental IL-7-dependent cells or those infected with a control vector. These results showed that IL-7 could participate in the malignant transformation of pre-B cells. However, neither of two Abelson murine leukemia virus (A-MuLV)-transformed pre-B-cell lines expressed detectable IL-7 mRNA, at a level of sensitivity corresponding to less than one molecule of mRNA per cell. Moreover, the proliferation of the A-MuLV transformants was unaffected by addition of the IL-7 antisera under conditions in which parallel experiments with IL-7 virus-infected cells resulted in greater than 70% growth inhibition. Thus, transformation of pre-B cells by A-MuLV was not associated with a demonstrable autocrine loop of IL-7 synthesis. These results show that IL-7 can participate in the malignant transformation of pre-B cells and suggest studies aimed at assessing the role of autocrine production of IL-7 in the generation of human leukemias and lymphomas.
authors.affiliation: Immunex Corporation, Seattle, Washington 98101.
authors.forename: R W
authors.initials: RW
authors.lastname: Overell
authors.forename: L
authors.initials: L
authors.lastname: Clark
authors.forename: D
authors.initials: D
authors.lastname: Lynch
authors.forename: R
authors.initials: R
authors.lastname: Jerzy
authors.forename: A
authors.initials: A
authors.lastname: Schmierer
authors.forename: K E
authors.initials: KE
authors.lastname: Weisser
authors.forename: A E
authors.initials: AE
authors.lastname: Namen
authors.forename: R G
authors.initials: RG
authors.lastname: Goodwin
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000166:cytology*; D015152:Blotting, Northern; D002455:Cell Division; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D002472:Cell Transformation, Viral; D003001:Cloning, Molecular; D015870:Gene Expression; D005822:Genetic Vectors; D006133:Growth Substances; D015851:Interleukin-7 / Q000502:physiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008979:Moloney murine leukemia virus; D009374:Neoplasms, Experimental / Q000503:physiopathology*; D009857:Oncogenes; D012333:RNA, Messenger / Q000235:genetics
chemical_list: D006133:Growth Substances; D015851:Interleukin-7; D012333:RNA, Messenger